Metastatic papillary thyroid cancers with malignant pleural effusion aggravated during thyroid hormone withdrawal for radioiodine therapy.
10.12701/yujm.2015.32.2.138
- Author:
Ji Hye SEO
1
;
Ji Hye JE
;
Hyun Jung LEE
;
Young Ju NA
;
Il Woo JEONG
;
Jee Hyun AN
;
Sin Gon KIM
;
Dong Seop CHOI
;
Nam Hoon KIM
Author Information
1. Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. pourlife@naver.com
- Publication Type:Case Report
- Keywords:
Thyroid neoplasms;
Thyroid hormones;
Malignant pleural effusion
- MeSH:
Aged;
Disease Progression;
Female;
Humans;
Hypothyroidism;
Iodine;
Lymph Nodes;
Middle Aged;
Neck;
Neoplasm Metastasis;
Neoplasm, Residual;
Pleural Effusion;
Pleural Effusion, Malignant*;
Pleurodesis;
Quality of Life;
Recurrence;
Thyroglobulin;
Thyroid Gland*;
Thyroid Hormones;
Thyroid Neoplasms;
Thyrotropin;
Thyroxine
- From:Yeungnam University Journal of Medicine
2015;32(2):138-142
- CountryRepublic of Korea
- Language:English
-
Abstract:
L-thyroxine (LT4) withdrawal prior to radioactive iodine (RAI) ablation therapy is a commonly used method for successful treatment of patients with papillary thyroid cancer (PTC). However, a prolonged period of hypothyroidism induced by LT4 withdrawal is sometimes associated with impaired quality of life and cardiopulmonary dysfunction in PTC patients. Furthermore, LT4 withdrawal may have a trophic effect on residual cancer by means of increased thyrotropin. We report on 2 cases of metastatic PTC patients with malignant pleural effusion (MPE) whose disease showed rapid worsening after LT4 withdrawal and RAI therapy. The first case is a 65-year-old woman who had PTC with multiple distant metastases and MPE. During LT4 withdrawal for RAI therapy, MPE showed rapid worsening, and the patient required repetitive therapeutic thoracentesis. The second case is a 49-year-old woman with PTC who underwent 3 additional operations for cancer recurrence in the neck lymph nodes and 6 times of RAI treatments. While preparing for the 7th RAI treatment by withdrawing LT4, she developed MPE which became progressively aggravated after RAI therapy. Both patients experienced increased pleural effusion during the LT4 withdrawal period and a rise in the thyroglobulin level was observed after RAI therapy. MPE was not controlled with therapeutic thoracentesis and pleurodesis. Eventually, both patients died of rapid disease progression after RAI therapy. In summary, LT4 withdrawal may have an adverse effect on metastatic PTC patients, particularly those with MPE.
